Haemacure Announces the Appointment of Two Senior Managers to its Management Team and the Staffing of the Manufacturing and Quality Teams
To further strengthen the Company's growing presence in the plasmafractionation industry, Haemacure has appointed Ms. Dawn Benson as Director ofQuality Assurance and Quality Control and Mr. Kenneth P. Smith as Director ofManufacturing. Both Ms. Benson and Mr. Smith will work from Haemacure'smanufacturing facility located in Sarasota, Florida.
Before joining Haemacure, Ms. Benson spent over 10 years in the qualityassurance and quality control fields, having held quality assurance positionsat several health care, consumer products and plasma fractionation companies.Mr. Smith brings to the team over 15 years of experience in the areas ofproduction and supervision, most recently with another plasma fractionationcompany.
In addition to the senior managers hire, Haemacure has also staffed theproduction and laboratory teams necessary to commission the manufacturingfacility.
"We are very excited to welcome all the new members of our growing team.Their valuable expertise will no doubt greatly contribute to achieving themilestones of commissioning our new manufacturing facility by mid-2008 andhaving a first patient undergo surgery in our planned pivotal Phase ll/Phaselll clinical trials during the first quarter of 2009," said Joseph Galli,Chairman and Chief Executive Officer of Haemacure. "We look forward to theircontribution in insuring that Haemacure meets its milestones and valuecreation objectives" concluded Mr. Galli.
Haemacure Corporation is a specialty biotherapeutics company developinghigh-value human plasma-derived protein products for commercialization.Haemacure's research and development effort is driven by its proprietaryplasma protein extraction technology to develop next-generation products,including surgical hemostats. Haemacure's lead product candidate,Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/PhaseIII clinical trials during the first quarter of 2009. Haemacure's secondproduct candidate is thrombin, a component of its fibrin sealant, now inpreclinical stage. Follow-on development will focus on surgical hemostats,wound healing, adhesion prevention, regenerative medecine, drug delivery andcombination with biomaterials. Haemacure has discovered eleven additionalspecialty proteins and enzymes in one if its two plasma fractions and seeks toadvance these proteins and enzymes through partnerships with pharmaceuticaland biotechnology companies. Haemacure operates offices in Sarasota, Floridathrough a wholly-owned subsidiary. The Corporation is traded under stocksymbol HAE on the TSX.
Certain of the statements contained in this news release areforward-looking statements. Such statements, based as they are on the currentexpectations of management, inherently involve numerous risks anduncertainties, known and unknown. Some examples of known risks are: the impactof general economic conditions, general conditions in the biotech industry,changes in the regulatory environment in the jurisdictions in which Haemacuredoes business, stock market volatility, fluctuations in costs, and changes tothe competitive environment due to consolidation or otherwise. Consequently,actual future results may differ materially from the anticipated resultsexpressed in the forward-looking statements. Haemacure disclaims any intentionor obligation to update these statements.
SOURCE HAEMACURE CORPORATION
You May Also Like